The Lancet Oncology in conversation with

Shankar Siva on radiotherapy for primary renal cell carcinoma

The Lancet Oncology

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv